Biogen Inc. (BIIB) News & EventsBIIBBiogen Inc.

Stock Futures Muted Ahead of Fed Rate Decision

Stock futures are muted Wednesday as investors await the Federal Reserve's interest rate decision and a round of technology earnings that could potentially shape market direction through the remainder of the summer.The Federal Reserve concludes its two-day policy meeting this afternoon, with markets expecting policymakers to leave the benchmark federal funds rate unchanged. The primary focus will be Fed Chair Kevin Warsh's post-meeting press conference for clues on how the central bank views inflation, economic growth and the path of interest rates.Corporate earnings remain the market's other major catalyst. Microsoft and Meta Platforms are scheduled to report after the closing bell, with investors looking for evidence that continued multibillion-dollar investments in artificial intelligence are translating into stronger cloud growth, advertising revenue and profitability.Semiconductor stocks remain under pressure following disappointing market reactions to earnings from South Korean memory chipmaker SK Hynix despite strong headline results. Investors continue to question whether AI infrastructure spending can support current valuations as competition from Chinese chipmakers increases.Investors will monitor developments in the Middle East after renewed regional tensions pushed oil prices higher, reviving concerns that energy-driven inflation could complicate the Federal Reserve's policy outlook. With monetary policy, Big Tech earnings and geopolitical developments all converging, markets are preparing for elevated volatility through the end of the week.In pre-market trading, S&P 500 futures slid 0.01%, Nasdaq futures fell 0.06% and Dow futures declined 0.64%.Check out this morning's top movers from around Wall Street, compiled by The Fly.UP AFTER EARNINGS -Manhattan Associatesup 13%Rocky Brandsup 12%Generacup 9%Amphenolup 6%Tevaup 6%Seagateup 5%Fordup 5%Deutsche Bankup 2%Biogenup 1%General Dynamicsup 1%DOWN AFTER EARNINGS -Lemonadedown 14%Vertivdown 10%VF Corp.down 9%Skyworksdown 8%Humanadown 4%Procter & Gambledown 3%NXP Semiconductorsdown 2%WMdown 2%SK Hynixdown 1%Visadown 1%OneMaindown 1%

Biogen Expects Mid-Single Digit Revenue Growth for 2026

Consensus $11.82. Full year total revenue is now expected to increase by a mid-single digit percentage for 2026 as compared to 2025 driven by continued revenue growth from our Growth Portfolio. Biogen expects combined Non-GAAP R&D expense and Non-GAAP SG&A expense to be between $2.65B and $2.70B for the second half of 2026. Apellis acquisition now completed with strong second quarter 2026 revenue performance for SYFOVRE and EMPAVELI. With the integration progressing well, Biogen expects approximately $0.85 dilution to Non-GAAP diluted EPS for full year 2026, driven largely by lower interest income and higher interest expense associated with the transaction financing, and remains on track for the transaction to be accretive to Non-GAAP diluted EPS in 2027. Transaction run rate synergies exiting 2027 are expected to be at least $250M